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Abstract 
The treatment for acute ischemic stroke is a delicate matter, especially since time relapse from 
ictus to treatment is of vital importance for the outcome. The constantly evolving treatment 
options aim towards achieving high revascularization rates and limit the time in order to 
prevent irreversible damage to the brain tissue. Although becoming more clear, predictors of 
positive outcome and selection of patients to receive endovascular treatment remains 
unproven. Promising results are seen when selection is based on imaging to determine still 
viable tissue and the localization of the occlusion. Furthermore it is known that 
revascularization is associated with improved outcomes, however it is still unclear which 
method, if any, is ideal and might be proven superior against the presently preferred medical 
treatment. The main goal of this review is to discuss available therapies for acute ischemic 
stroke and criteria that will help identifying patients who might benefit from them. In order to 
find selection criteria and decide whether endovascular treatment is superior to medical more 
randomized controlled studies are needed. 
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Abbreviations 
ASPECTS: Alberta Stroke Program early CT Score. A 10-point quantitative topographic CT 
scan score used to detect early stroke changes on a CT-scan.  
NIHSS: National institute of health stroke scale. Tool used to objectively quantify the 
impairment caused by a stroke. 
CT-caput: Computed tomography of the head used in stroke treatment to diagnose and differ 
between intracranial bleeding and ischemic strokes. 
NCCT: Non-contrast computerized tomography 
MRI: A medical imaging technique used in radiology to investigate. MRI scanners use strong 
magnetic fields and radio waves to form images of the body. 
ICA: Internal Carotid Artery 
MCA: Middle Cerebral Artery 
ACA: Anterior Cerebral Artery 
VBA: Vertebrobasiliar artery 
IVT: Intravenous Thrombolysis used to dissolve occlusions with the use of recombinant tissue 
Plasminogen Activator (rtPA) administered systemically.   
IAT: Intra-arterial Thrombolysis. This delivery technique permits high concentrations of a 
lytic agent to be applied locally to the occlusion while minimizing systemic exposure.  
Endovascular therapy: Therapy performed from the inside of a vessel via a catheter. 
Modified ranking scale (mRS): commonly used scale for measuring the degree of disability or 
dependence in the daily activities of people who have suffered a stroke. 
Penumbra: The area surrounding an ischemic event such as an ischemic, thrombotic or 
embolic stroke that is not efficiently perfused but is still vital. An area that may still be 
salvaged by treatment.   
TIMI/TICI: Thrombolysis in Myocardial Infarction/Cerebral infarction. A scale used to 
measure blood flow after recanalization of an occluded vessel. 
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Introduction 
The first description of stroke dates back to the days of Hippocrates. He described episodes of 
convulsions, impaired speech and paralysis in patients. Because the onset was so sudden he 
called it “apoplexy” meaning “struck with violence” in Greek (1).  
        Great advances were made when English physician Thomas Willis described the 
intracranial arteries, especially the ones known as the Circle of Willis. Later, during the 
nineteenth century R.L.K Virchow was the first who postulated that stroke was the cause of 
ruptured vessels or thromboembolic events. To describe the downstream loss of perfusion, 
Virchow established the term “ischemia”.  The same century Charles Foix traced the deep and 
superficial arteries and correlated them to clinical signs. Ever since Charles Foix and his 
contribution to the studies of stroke, the knowledge and treatment of it has grown 
exponentially. New techniques in diagnostics, imaging and treatment of ischemic stroke is 
constantly evolving (1). The handling of patients undergoing diagnostics for ischemic stroke 
is a delicate matter. However, it is still not defined what selection criteria to use when 
deciding on treatment options.  Time from onset of symptoms is of the essence, but equally 
important is the localization of the thrombus. Identifying collateral circulation is important in 
evaluating outcome, as well as the primary therapeutic efforts. 
 Apart from this is the fact that there are now several different types of treatments. One 
usually divides them into medical and endovascular recanalization. Intravenously 
administered recombinant tissue plasminogen activator (rtPA) is the most commonly used 
treatment aiming towards dissolving the thrombus. In the other part of the spectrum is the 
endovascular mechanical recanalization of the thrombus. The latter one is used with the help 
from imaging done in interventional laboratories. Access to the occluded vessel is most 
commonly gained from introducing a guided wire through the femoral artery. The wire is then 
guided up to the intracranial occluded vessel where it is used to open it mechanically with or 
without the administration of actilyse. More studies now point in the direction that 
interventional recanalization might be the preferred treatment in occlusions presenting in 
large intracranial arteries. Patients with occlusions in the major cerebral arteries experience 
the most severe impairments such as reduced daily function, speech and paralysis.  
Stroke is the third most common cause of death in Norway and the most common cause of 
long-term impairment of daily function and treatment. It is stated that a great proportion of 
reduced function in the people who experience a stroke can be prevented if fast ways in 
diagnosing and giving the patients efficient treatment were available.  
 During the last 10-20 years the management of ischemic stroke has changed 
tremendously. Earlier the only option was rehabilitation. Though rehabilitation still is a 
cornerstone in treating patients who experience a stroke, there are of course still much to be 
achieved regarding ideal stroke treatment in the future.  
         When diagnosing large intracranial occlusions prehospital skilled personnel are of high 
importance. In addition strategies of communication between the ambulance transporting the 
patient and specialized stroke units help reduce the time from onset of symptoms to adequate 
treatment. The hospital admitting the patient must have effective and standardized algorithms 
in order to not stall the initiation of treatment.  
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Methods for literature search 
A literature search was performed in McMaster PLUS through “helsebiblioteket.no” using the 
terms “Endovascular AND ischemic stroke”. Other studies were found searching pubmed 
using the terms “acute ischemic stroke AND prognostic factors”, “endovascular treatment 
AND stroke” and “Stroke AND imaging”. Only articles in English and Norwegian were used. 
 
Methods: What may improve flow? 
 
IVT: Intravenous treatment  
Administration of alteplase (a tissue plasminogen activator) is the standard treatment for acute 
ischemic stroke. It remains the only approved therapy by the FDA (the US food and drug 
administration). Alteplase administration is associated with good outcomes if it is given 
within 3 hours from onset of symptoms. In 1995 the NINDS study studied the difference in 
outcome when treating patients with ischemic stroke with alteplase vs. a placebo. The study 
showed superior results as compared to placebo, when the treatment was initiated within 3 
hours after onset of symptoms. It was concluded that despite the increased incidence of 
haemorrhage improvement in clinical outcome at three months was found (2).  
        In the third international stroke trial (IST-3) carried out by Sandercock et al (3) the 
studies intention was to determine whether or not patients might benefit from IVT up to 6 
hours after symptom onset. In this international, multicentre, randomised study it was 
concluded that despite the early hazards, thrombolysis within 6 hours improved final 
outcome. Furthermore it concluded that benefit was not reduced in patients who were older 
than 80 years. Still, the issue concerning intracranial haemorrhage (ICH) remained showing 
an increased incidence in the group treated with alteplase. However, according to the 
guidelines stated by the AHA/ASA (the American Heart Association/the American Stroke 
Association) the time period remains 3,5-4 hours from onset of symptoms. The ECASS III 
study confirmed that patients might benefit from IV rtPA from 3-4,5 hours (4). Multicenter 
trials performed between the one carried out by the NINDS study group and IST-3 have 
shown largely similar results in the time window from onset to treatment initiation (5). 
Seeing IVT is the most readily available method in achieving recanalization after an ischemic 
stroke it is still the most used treatment now.  
 
 
Intra-arterial fibrinolysis. 
This method uses a micro catheter placed into the proximity of the occluded artery. Once in 
place the operator infuses the fibrinolytic substance in order to dissolve the thrombus. There 
are two randomized trials that show support for the use of intra-arterial fibrinolysis: The 
PROACT II study and the Middle Cerebral Artery Embolism Local Fibrinolytic Intervention 
Trial (MELT). The PROACT II study was the first randomized multicenter trial sought to 
demonstrate efficacy of intra-arterial thrombolysis in patients with acute stroke caused by 
MCA occlusion (6). A total of 180 patients who presented less than 6 hours after symptom 
onset were randomized to receive either intra-arterial (IA) prourokinase (proUK) plus heparin 
or heparin alone. The outcome was measured and based on the proportion of patients with 
neurological disability at 90 days. The results stated that 40% of the proUK and 25% of the 
control patients had a modified ranking scale (mRS) of 2 or less at 90 days (P=0.04). 
Furthermore patients treated with proUK reached independence in activities of daily living 
 7 
earlier although this was not of statistical significance at 90 days (P=0.24). Middle cerebral 
artery (MCA) recanalization was achieved in 66% of the r-pro-UK arm and 18% of the 
control group (P<0.001). Despite these positive results the fact remained that post-procedural 
haemorrhage was more frequent in the interventional group. Within 24 hours intracranial 
haemorrhage with neurological deterioration had occurred in 10% of the patients receiving 
proUK and 2% of the ones receiving heparin alone. However at 10 days the percentage of the 
ones experiencing intracranial haemorrhage in the intervention contra the control group was 
68% and 57% respectively (P=0.23). The study concluded: “PROACT II has demonstrated 
that the therapeutic window for a significant number of patients with major stroke due to 
MCA occlusion may extend to at least 6 hours”. The issue remains finding the patients who 
might benefit from the treatment at that time point.  
        The MELT study carried out in Japan was a trial which randomized patients with 
occlusion in M1 or M2 presenting within 6 hours to either receive IAT (intra-arterial therapy) 
with urokinase or control (7). It was discontinued prematurely because of the approval of 
intravenous infusion of tissue plasminogen activator in Japan. Before the discontinuation of 
the study it had showed positive results, however, not reaching statistical significance it was 
concluded that the analyses showed that intra-arterial fibrinolysis has a potential to increase 
functional outcome.   
       Although lack of evidence intra-arterial approach is thought to be more effective for 
treatment of the more proximal arterial occlusions as compared to the intravenous treatment. 
A NIHSS over 10 and imaging pointing towards the occlusion of a major intracranial artery 
indicates a potential for good outcome when treating a patient with intra-arterial thrombolysis. 
Although the studies carried out so far show promising results there are still missing data in 
order to prove its superiority vs. intravenous rtPA (5).   
 
 
Bridging. 
It is understandable that when treating ischemic strokes with endovascular methods a delay to 
initiation of therapy is inevitable. Furthermore, it has been seen that rtPA alone has a lesser 
chance of achieving recanalization in the event of occlusions in more proximal arteries (8). 
Therefore, it has been proposed that treating strokes with administration of rtPA before intra-
arterial fibrinolysis might help in raising the efficacy. The Interventional Management of 
stroke (IMS) II Study showed promising results (9). It was a multicenter study that screened 
patients at 13 clinical sites in North America. The subjects included in the study were first 
treated with IV rtPA. The ones that had arterial occlusion at angiography received additional 
rtPA through a micro-infusion catheter at the site of the thrombus.  In the discussion it was 
stated that the patients who participated in the IMS II study were significantly more likely to 
have an excellent outcome at three months. This compared to the individuals who had 
participated in the NINDS rtPA Stroke trial mentioned above. 
        Because of the results presented in the IMS II study the IMS III study was initiated in 
2006 (10). The goal was to enrol 900 subjects with a NIHSS of 10 or more. The ones 
randomized into the intervention group after receiving IV-rtPA were supposed to receive 
further treatment with either the EKOS Micro-Infusion, MERCI thrombus-removal device, 
the Penumbra System, the Solitaire FR device or infusion via a standard micro catheter. Those 
were the aims presented. The study was stopped early due to futility after 656 patients had 
undergone randomization. The proportion of patients with a mRS of 2 or less after 90 days 
did not differ between the intervention and control group. The study further highlighted that 
improved revascularization after the procedure was not a guarantee of clinical efficacy as 
compared to IVT alone. In the study, due to early stop, only a few patients were treated with 
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stent retrievers (a newer generation thrombectomy device). It concluded that the efficacy of 
the new devices as compared with IV rtPA alone remains to be demonstrated.  
        Another study presented in Radiology in 2013 performed by Roubec et al. showed more 
promising results (11). The purpose of their study was to compare the safety and utility of 
intra-arterial revascularization with stents to no mechanical revascularization in patients who 
failed to respond to IVT or had contraindications to it. Group 2A and 2B comprised of the 
patients who had IVT failure and received intravascular therapy or no further treatment 
respectively. There was a significant difference in favourable outcome at 3 months being 
43.5% in 2A and 15.4% in 2B (P=0.03) indicating the potential in combining the use of IVT 
and endovascular therapy.  
     
 
MERCI 
The Merci retriever was the first device used for mechanical extraction of a thrombus. The 
device consists of a long wire with a helical coil formed at the end. When the retriever goes 
through the thrombus the coil reforms around the clot allowing it to be pulled back through 
the catheter. In the MERCI trial published in Stroke 2005 the results were promising (12). In 
this nonrandomized multicenter trial patients were treated with the device if they presented 
within 8 hours after stroke onset. Recanalization was seen in 48% of the patients in whom the 
device was used. Furthermore, a mRS at or below 2 was seen more frequently in patients who 
experienced recanalization as compared to those who did not (46% versus 10%, P<0.0001). 
Not only was the study showing positive results as regards to recanalization and low numbers 
of mRS, more importantly, it concluded that it was possible to reopen occluded vessels within 
8 hours after symptom onset and that it actually was a safe alternative when contraindications 
towards thrombolytics existed. Compared to the NINDS, IMS trial and PROACT-II study it 
also had less frequent complications in forms of haemorrhage. 
        Three years later came the results from the Multi MERCI trial (13). This was an 
international, multi centre, prospective study in which patients who had received IV rtPA but 
still had large vessel occlusion was included. In this study a newer generation device was 
used, however not reaching the point of statistical significance in recanalization as compared 
to the older generation. The study was indeed important as it further supported the correlation 
between the degree of recanalization and good clinical outcome. This was not a controlled 
study so it was unable to prove that thrombectomy improves stroke outcomes.  
 
PENUMBRA 
The Penumbra stroke system consists of an aspiration pump, reperfusion catheters and 
separators. By placing a reperfusion catheter at the proximal end of the thrombus and 
connecting it to a vacuum pump, aspiration of the thrombus is made possible. By advancing 
and withdrawing the separator the goal is to debulk the thrombus into smaller pieces while 
keeping a steady suction to achieve recanalization. The Penumbra pivotal trial sought to see 
whether or not the Penumbra System was safe and effective in reducing clot burden in 
patients with large vessel occlusions (14). Revascularization occurred in 81.6% of the 
patients. Lower numbers of ICH were reported as well. Twenty-five percent had either a 
NIHSS score of 0-1 or a 10-point improvement at discharge.  The same percentage was seen 
in the patient group with a mRS under 2 at 90 days. This was comparable to the MERCI trial 
but lower than the PROACT II study. This was unexpected seeing that a high amount of 
patients experienced successful revascularization. According to the authors the reason for this 
remains unclear. They do, however, state that the possibility of the Penumbra System not 
improving the patients activities of daily living at 90 days seems unlikely because analysis of 
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open versus closed vessels in the study showed a benefit in all measures in neurological and 
functional status, including mortality. Another possibility, they continue, might be the small 
number of patients included in the study. The study proved that the Penumbra system was 
indeed a safe and effective as regards to revascularization in patients with ischemic stroke 
treated within 8 hours. However, this was not a controlled trial. In order to prove the 
Penumbra Systems superiority over IV-rtPA in post procedure neurological recovery, 
controlled trials will be the deciding factor. 
        One year later a retrospective case of 157 patients from seven international centres was 
performed (15). The results showed even higher numbers of revascularization and 41% of the 
patients included had a mRS at or below 2. No major difference between the groups studied in 
the pivotal and post study was indentified. The differences in the results as regards to mRS at 
90 days remain unclear. 
 
 
Stent Retrievers 
This is a newer generation device for thrombectomy. The access to the occluded vessel is 
through the femoral artery. The catheter is guided to the occluded vessel and then used to 
penetrate it. As the catheter is pulled back the stent is deployed and traps the thrombus in 
order to retrieve it. 
        There is one international, multicenter, prospective, single arm study published in 2013 
that tested the Solitaire system (16). It included 202 patients from 14 stroke centres across 
Europe, Canada and Australia. Only patients with occlusions in the anterior circulation were 
enrolled. The study showed that the Solitaire Flow Restoration device achieved successful 
revascularization in patients with anterior occlusion as well as low numbers of ICH and 
mortality. The low mortality at 90 days being 6.9% was hypothesized to be correlated to the 
imaging based patient selection limited to anterior circulation strokes. mRS at 90 days at or 
below 2 was 57.9%. As this was not a randomized controlled study it concluded that the 
positive results supported further investigation in randomized controlled trials against medical 
treatment alone.  
        The TREVO device is another stent retriever that works in a similar way as the Solitaire 
device. A study published in 2013 provided data that the TREVO system was a safe and 
effective alternative for patients who had a stroke and were treated within 8 hours (17). 
Among the 60 patients who were enrolled the recanalization rate was 91.7% (thrombolysis in 
cerebral infarction (TICI) score at or above 2a) and a 90 day mRS at or below 2 was seen in 
55%. Again promising numbers were presented. However, as in preceding studies, 
randomized controlled studies comparing stent retrievers against medical treatment are 
necessary to determine their superiority.  
 
Comparing endovascular treatments. 
Presently there are two major studies that have compared different endovascular treatments 
against one another. Those are the SWIFT and TREVO 2 study.  The SWIFT study was a 
randomized, parallel study that enrolled patients to either receive treatment with the Merci- or 
Solitaire device (18). The results presented in Lancet in 2012 showed significant better results 
pointing towards the Solitaire device. Recanalization without symptomatic ICH was seen in 
61% with the Solitaire- and 24% with the MERCI device. Further, mRS at 90 days was more 
favourable in patients treated with the Solitaire device. This study was halted early as the pre-
specified criteria when to stop the study were met. This was an important study as it was the 
first one comparing two revascularization devices.  
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        The second one, the TREVO 2 study compared the TREVO and the MERCI device (19). 
Again the MERCI one fell short against a stent retriever. In this study patients at 26 different 
sites were enrolled. The patients were randomized to receive treatment with either the MERCI 
or TREVO device. The study showed that revascularization was accomplished more often in 
the TREVO group. The mRS at 90 days at 2 or below was 40% in the TREVO group and 
21.8% in the MERCI group. These two studies show that the stent retrievers are in fact 
superior in means of revascularization of occluded vessels as well as accomplishing better 
independence 90 days after an acute ischemic stroke. 
 
 
Predictors of positive outcome 
One of the most essential foundations in stroke therapy is rapid clearance of a thrombus to 
restore blood flow in the occluded vessel. The term “time is brain” was therefore introduced 
meaning that for every minute a vessel remains occluded tremendous amounts of neurons 
dies. However, selection criteria for whom to treat in terms of endovascular therapy contra 
intravenous have not been well postulated. 
 
Role of imaging 
Imaging will always have an important role in the treatment of acute ischemic stroke. CT of 
the brain is one of the cornerstones seeing that there are no other certain ways of 
differentiating between stroke due to occlusion or haemorrhage. Ordinary CT of the brain has 
a low sensitivity in showing early changes in infarction and not fit for selecting patients who 
are most likely to benefit from endovascular thrombectomy. On the other hand CT or MRI 
with perfusion-weighted sequences are able to identify the penumbra. This is the brain 
volume surrounding the infarct core with reduced perfusion but may still be salvaged if blood 
flow is normalized.  Due to this the DEFUSE 2 study  published in Lancet 2012 sought to 
establish whether a MRI could identify patients who would benefit from endovascular therapy 
(20). The results where positive and showed that target mismatch, mismatch between the 
infarct core and hypoperfused area, in patients prior to successful reperfusion had better 
clinical outcome in terms of reduced mRS at 90 days. The authors concluded that a 
randomized controlled study with patients eligible for endovascular therapy with a mismatch 
on imaging would be necessary. Unfortunately a second study presented in the New England 
Journal of Medicine in 2013 did not show any superiority in outcome when this was done 
(21). This was a randomized trial in which patients with anterior circulation occlusions where 
assigned to either mechanical thrombectomy (Merci retriever or Penumbra system) or 
standard care (rtPA) within 8 hours after stroke onset. Before initiating treatment the patients 
underwent a CT scan or MRI in order to see whether or not the patients had a mismatch 
pattern or not. The results not only failed to show that patients with a mismatch pattern on 
neuroimaging would benefit from endovascular therapy, additionally endovascular treatment 
did not show any superiority against standard medical treatment. The authors state that the 
study highlight questions, one being the low recanalization rate in the embolectomy group. 
This might be due to the fact that only first generation devices were used although the newer 
stent retrievers have proven more effective in accomplishing fast recanalization. Moreover, 
this study had a longer time to treatment than the DEFUSE 2 trial, again highlighting the 
importance of early recanalization. In 1998 a study was initiated that aimed to study whether 
intra-arterial or intravenous thrombolysis would be more effective for patients with a 
hyperdense middle cerebral artery sign (HMCAS) on CT (22). In this observational study the 
patients receiving intra-arterial thrombolysis were proven to benefit more than the ones 
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receiving intravenous if they presented with a hyperdense MCA sign. Another study 
published in Stroke hypothesized that the final stroke volume was in fact the true image 
predictor in patients who underwent endovascular therapy (23). The authors identified 
patients with an anterior circulation stroke who had undergone final infarct imaging. The 
results showed correlation between the final infarcted volume and mRS at 3 months. They 
concluded that a smaller final infarct volume is the best predictor of 3-month functional 
independence. The presently ongoing DAWN trial is a retrospective multicenter study 
enrolling patients who were last seen well 8 hours or more before having a confirmed 
occlusion in an anterior circulation proximal vessel by angiography (24). The preliminary 
results are indicating that endovascular treatment can safely be used after 8 hours as long as 
selection is based on perfusion imaging.  
        Seeing that CT has to be done before IV therapy can commence it has been speculated in 
ways to predict outcome in stroke treatment. One of these non-contrast CT (NCCT) methods 
used for evaluating early parenchymal injuries is the Alberta Stroke Programme Early CT 
Score (ASPECTS) (25). The scoring system comprises 10 regions in the MCA perfusion 
territory. One point reduction is counted if one territory of the ten appears to be affected by 
ischemia. Studies have shown that an ASPECTS score at or above 7 predicts good clinical 
outcome after endovascular treatment (26).  
 
Selection of patients and techniques 
According to studies the effect of rtPA reduces with time and more proximal occlusions. 
Furthermore, the risk of re-occlusion enhances with time. Recanalization rate of the middle 
cerebral artery and the internal carotid artery is said to be as low as 25% and 10% respectively 
when using alteplase (27). In addition the fact that patients may respond differently to IV-
rtPA have resulted in the search for different ways of opening occluded vessels. In order to 
select patients who are eligible for treatment one must first identify what may predict good 
clinical outcome.  
        In a study published in 2012 the authors prospectively acquired data from patients who 
had infarcts in the carotid artery territory (the carotid, the middle and the anterior cerebral 
artery) who received endovascular therapy (28). The study continued between 1992 and 2010 
when the endovascular treatment had evolved substantially. On admission NIHSS was scored 
and other clinical data was gathered. CT or MRI was performed in order to localize the 
occlusion as well as classify collateral vessels. Clinical outcome was registered at 3 months. 
The study concluded that a next day post recanalization improvement in NIHSS was 
associated with improved outcome and survival at 3 months. Furthermore, when more 
variables were analysed good collaterals, successful recanalization and hypercholesterolemia 
proved to be the strongest predictors for survival. The location of the occluded vessel also 
predicted outcome (see later). Good outcome at 3 months (mRS at or below 2) was predicted 
by better recanalization, hypercholesterolemia, lower NIHSS on admission, young age, 
absence of diabetes and good collaterals. Surprisingly, time from onset of symptoms did not 
predict outcome when collaterals was included in the multivariate model, only when it was 
excluded. This suggests that collaterals have a major role to play in the selection of patients 
available for endovascular therapy. This has been proven in other studies as well (29). 
Although this was a single centre non-blinded study it suggests that collaterals play a crucial 
part for the longer treatment window expected when compared to IVT. In the trial the 
majority of patients had occlusions in the internal carotid artery and the MCA. These have 
more collateral channels than the peripheral ones. Seeing that proximal occlusions have a 
higher chance of recanalization than distal ones, endovascular treatment might be especially 
promising in such cases.  
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The first systematic review correlating recanalization to clinical outcome was a meta-analysis 
performed by Rha et al (30). It included 53 studies with the total amount of 2066 patients. It 
confirmed the association between recanalization and outcome. The pooled analysis of the 
MERCI and Multi MERCI trials published in 2009  also concluded that final recanalization 
represents the strongest predictor of clinical outcome both in the univariate and multivariate 
analyses (31). mRS 0-2 was seen more frequently in patients who experienced a thrombolysis 
in myocardial infarction (TIMI) score of 2-3. Similarly, younger age and lower NIHSS were 
also strong positive predictors. Occlusions in the ICA demonstrated to be an independent 
predictor of mortality but do not decrease the chance of good outcomes after thrombectomy. 
There is still a debate surrounding whether or not blood pressure should be optimized during 
stroke treatment. On the one hand it has been postulated that a higher blood pressure might 
protect the brain by increasing perfusion pressure to the penumbral tissue. On the other hand 
it is hypothesized that an elevated pre-treatment systolic blood pressure is related to poorer 
collateral flow. The pooled analysis showed that hypertension has a negative impact on 
recanalization and suggest that a further understanding of physiology is needed before 
implementing management of blood pressure in guidelines. 
  
Making the decision of therapy further complex, size of the occlusion also plays a part. Riedel 
et al. in 2011 hypothesized that the recanalization of occluded vessels depends on the length 
of the thrombus (32).  In their study they included 138 patients who presented with acute 
MCA stroke and who were treated with rtPA. The clot size was measured in terms of length 
and depicted as arterial hyperdensities on nonenhanced CT. The study showed that IVT has 
very moderate chances of achieving recanalization in a thrombus exceeding 8 mm.  
        
 
Localization 
The localization of an occluded vessel is usually divided into the ones occurring in the 
anterior and the posterior circulation. The posterior circulation comprising the major arteries 
of the left and right vertebral arteries, the basilar artery and the two posterior cerebral arteries. 
The anterior circulation comprising the right and left internal carotid arteries and their 
branches, mainly the middle cerebral artery (MCA) and the anterior cerebral artery (ACA). 
Untreated the localization of the occlusion has impact on mortality. Studies suggest that a 
complete MCA stroke has a mortality of 78% (33). Meanwhile for basilar occlusion 80% 
disability or death might be seen (34). 
 
 
Posterior circulation 
Ischemic strokes in the posterior circulation accounts for approximately 20% of the total 
amount. Despite the evolvement in the treatment of acute ischemic strokes the results are not 
as applicable to patients with occlusions in the basilar artery. There are many reasons for this, 
the most prominent being the lesser amount of patients with occlusions in the posterior 
circulation and the fact that no studies have included only occlusions in the posterior 
circulation in randomized controlled trials (34). In the only multicenter study that was 
initiated to randomize patients to either intra-arterial urokinase or anticoagulation alone the 
recruitment was so poor that no conclusion in terms of safety and efficacy could be drawn 
(35). The BASICS study was a prospective observational study that assessed outcomes in 
treatment of occlusions in the basilar artery (34). Stroke severity was divided in mild to 
moderate and severe. The treatment was divided into antitrombotic treatment only, 
intravenous treatment and intra-arterial treatment. The study failed in showing any superiority 
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of intra-arterial treatment against intravenous but has resulted in the ongoing randomized 
controlled BASIC study (36). This study will enrol patients specifically with occlusions in the 
posterior circulation and randomize them into endovascular therapy or intravenous. Results 
are pending.    
        Another multicenter study, which enrolled 180 patients with acute vertebrobasiliar 
occlusion, who were treated with intra-arterial fibrinolysis, evaluated outcome retrospectively 
(37). The result showed that recanalization, whether partial or complete was significantly 
associated with a positive outcome (P=0.001), however being more positive with complete 
recanalization. The success of recanalization was also associated with the volume of the 
thrombus, being less effective if the thrombus volume exceeded 300 microL. These results 
support the hypothesis presented earlier that the true goal of endovascular treatment should be 
early and effective recanalization and that it holds true for posterior circulation occlusions as 
well. 
 
 
Anterior circulation  
The study of 623 patients with anterior vessel occlusions who received endovascular therapy 
performed by Galimanis et al. presented the clinical outcome in specific vessels in the anterior 
circulation (28). 16.5% of the patients had occlusions in the internal carotid artery, 12% in the 
carotid T (intracranial carotid bifurcation occlusion with involvement of the A1 and M1 
segments), 44.6% in the M1 segment of the middle cerebral artery, 16% in the M2 segment, 
8.7% in the M3/4 segment and 1.3% in the anterior artery. Two or more vessels were 
occluded in 19.6%, the combination of proximal carotid artery and the middle cerebral artery 
being the most frequent. Interestingly enough the outcome was dependent of the occluded 
vessel. For instance proximal occlusions had better chances of recanalization than distal.  
Even more interesting is the paradox fact that these occlusions were the ones with the worst 
clinical outcome at 90 days. In the internal carotid artery recanalization was seen in 85.4% of 
the patients but only 37% of them had a mRS at or below 2 at 90 days. In the patients with 
carotid T occlusions 62.7% received successful recanalization, however, only 13.3% had a 
mRS at or below 2 after 90 days. According to the authors this is most likely because the 
carotid T occlusions cut of the circle of Willis, a very important channel for collateral 
circulation.  
        The localization is an important predictor of outcome not only because the limitations of 
reaching the thrombus but also because the specific vessel anatomy of the brain. As stated 
earlier collateral circulation has a tremendous role to play in the clinical outcome of treated 
patients after 90 days. The localization of the occlusion not only reduces blood flow distal to 
it but also inflicts on the way collateral blood flow appears. The infarct area is larger the more 
proximal the occlusion is. The worst outcome is seen in occlusions in carotid T occlusions 
(occlusions comprising the bifurcation on the most cranial part of the carotid artery) due to 
the limited supply to and from the other normal side through the circle of Willis. In one study 
the authors also describe cases where partially lysed occlusions in the carotid T have migrated 
distally and initiated occlusions in MCA and ACA. This hampers retrograde filling of the 
leptomeningeal collaterals and further reduce the clinical outcome (29). Since these more 
distal occlusions might be harder to reach it might indicate that a functional stroke centre need 
both treatment choices: Endovascular to achieve quick recanalization of proximal large 
occlusions and IV-therapy for opening distal occlusions that might reduce retrograde 
collateralization. The pooled analysis of the MERCI trial concluded that although ICA 
occlusions have increased rates of mortality they do not decrease the chances of good 
outcomes after thombectomy (31).  
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Status in Norway 
Norway is a very diverse country in terms of terrain. Furthermore it has a small and very 
scattered population. Seeing one of the most important predictors of good clinical outcome is 
early recanalization this postulates obstacles in the treatment of these patients. Every year 
approximately 15000 face a stroke in Norway. In the future this figure will continue to grow 
because of an older population. Patients experiencing an ischemic stroke is a very 
heterogeneous group an therefore the best treatment is an individual carefully planed one (38).  
 
The organisation in stroke treatment is divided into primary and specialized stroke units. One 
can find several reasons why IV-therapy is the treatment of choice in several stroke units. It 
can be initiated minutes after a NCCT has ruled out haemorrhage and the administration of 
rtPA does not need to be handled by a physician with any specific training as opposed to 
endovascular treatment. However, as earlier stated, IV-treatment is proven inferior against 
endovascular therapy in accomplishing recanalization of larger more proximal occlusions 
(39). Additionally there are several contraindications that rule out treatment with rtPA thereby 
making some of these patients eligible for the endovascular option. Looking at stroke 
treatment today in Norway only a few patients get referred to the specialized stroke units to 
receive endovascular therapy, the exception being the primary stroke units in the proximity of 
the specialized ones (40). Present guidelines state that a stroke patient is to be transported to 
the closest primary stroke unit. Although this might help to reduce the time to initiation of IV-
treatment it might also delay the initiation of adequate interventional treatment if this proves 
to be an eligible patient. The time lost might be substantial if a patient first is transported to 
one unit, only to be transported to a specialized one when the diagnostic criteria for 
endovascular treatment are fulfilled. The key element, one might propose, to efficiently 
finding patients to transport to the specialized units is early prehospital selection. Specially 
trained ambulance personnel who can contact the specialized units when in doubt could 
manage this. One proposition is to decentralise more of the decision making to earlier 
instances so that patients are transported to the right place at once. The establishment of 
dedicated mobile stroke teams is another option. These could be summoned to patients with 
more severe stroke symptoms and help in the decision making in whom to send to the 
specialized units. One study used a mobile stroke unit (MSU) equipped with a CT-scanner, 
point-of-care laboratory and telemedicine connection (41). It showed that the use of a MSU 
reduced the time from alarm to therapy decision significantly being 35 minutes in the in the 
interventional group and 76 minutes in the control group (P=0.0001).   
          
The primary centres are capable of administering rtPA meanwhile the specialized ones handle 
the endovascular procedures. There are currently 4 specialized units in Norway. The 
management of stroke patients should be organized in a way making it possible to identify 
those eligible for endovascular therapy. If one looks at the information presented above there 
are in fact some indicators that may point in the direction of who may benefit from the 
therapy, one of them being imaging. Studies show that large proximal occlusions exceeding 8 
mm in length have less probability in getting recanalized with the use of IV-rtPA only. In 
order to find these occlusions NCCT is not sufficient. The use of CT with the addition of a 
contrast agent must always be evaluated otherwise potential patients might be overlooked. 
Many primary stroke units have these imaging possibilities but there are still those who do 
not. Furthermore, some of the primary stroke units lack the advantage of having continuous 
communication with a radiologist part of the day. This is of utter importance when deciding 
between the different types of treatments (40). Since there are studies that show positive 
 15 
results treating patients with prolonged symptoms over 8 hours, perfusion-CT and MRI 
should be included in the diagnosing of particular patients. This might be economically and 
administratively challenging, although, seeing stroke therapy is constantly evolving and 
literature is pointing towards the importance of adequate imaging in the diagnostics, a lot of 
primary stroke units will have to change their routines in the management in acute ischemic 
stroke in the not too distant future. This could be a cost benefit factor for the healthcare in 
Norway since the growing older population will need substantial more prolonged and 
expensive rehabilitation after having suffered from a stroke. 
         Norway has an excellent ambulance transport service with helicopters and airplanes. 
This sets the foundation for inclusion of a larger population who could be treated with 
endovascular therapy seeing there are fewer obstacles in transporting patients from remote 
areas to the more central hospitals. Since Norway has a small and scattered population 
keeping the specialized units enables a steady flow of patients receiving up to date care.  This 
does not only help to raise the amount of procedures done but also keep education and skills 
at an adequate level (42). 
 
 
Results and discussion 
The treatment and the way we look at stroke treatment today have changed tremendously over 
the last 20 years ranging from IV-rtPA to mechanical endovascular thrombectomy devices. 
Since individual responses to IV alteplase are very heterogeneous, additional intra-arterial 
thrombolytic and mechanical endovascular treatment is used more frequently. Although these 
devices have been proven to be very efficient in terms of recanalization and outcome in the 
single arm studies, data from randomized clinical trials have failed in showing their 
superiority against intravenous therapy alone. So far there are three studies that have tried to 
prove that the endovascular option leads to a better outcome. These are the IMS III, MR 
RESCUE and the SYNTHESIS EXPANSION trials (10, 21, 43). Showing discouraging 
results these studies have been the aim of major criticism because of the methods used in the 
respective trials. Quershi et al. bring up several points, one being the low NIHSS score of 
several patients who were included (44). This might point towards a favourable outcome 
regardless of treatment. It is particularly the SYNTHESIS trial that failed in this seeing they 
did not have any pre-specified NIHSS score that would include or exclude patients in the 
study making the results hard to interpret. Additionally, although imaging is an important 
factor CT or MR angiography confirming arterial occlusion was not required in the the IMS 
III and SYNTHESIS trial. This might be a confounding factor since there are studies 
supporting the use of CT angiography for determining the patients who might benefit from 
intra-arterial thrombolysis. Another point presented in the studies is the low number of 
patients with an occlusion in the posterior circulation. In the MR RESCUE trial none were 
included. The mortality rate remains high in these occlusions when using IV alteplase 
pointing towards the potential beneficial use of endovascular therapy. Moreover, it is 
hypothesized that outcomes in the 3 studies would have been different if a larger population 
had received treatment at an earlier state and had been treated with the newer stent retrievers.  
 
Summary 
Summarizing the material in this critical analysis one might see that there are still unanswered 
questions. Many investigators, including myself do not feel certain that endovascular 
treatment is proven to be inferior or even equal to intravenous thrombolysis. Based on the 
selection criteria for inclusion in the studies so far they are still considered to be non 
standardized and even random at some points. However, the fact remains, endovascular 
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therapy have been proven to be inferior in several studies although they show promising 
results in the single arm ones.  Applying the knowledge gained from the IMS III, 
SYNTHESIS EXPANSION and MR RESCUE to general practise is, in my opinion, a bit to 
early to do seeing that there are still grounds to be covered. More randomized studies with 
clear and well-formulated inclusion criteria are needed. The aim should be focused on finding 
solid proof that help selecting patients who can benefit from endovascular therapy seeing 
there is a big probability that more patients are eligible candidates. Clear-cut criteria and easy 
to understand logarithms in terms of whom to send forward should be standardized, being less 
complicated at earlier stages and reliant on more expertise and diagnostic tools at later ones. 
One model would be the possibility to decentralize decision making to ambulance personnel 
giving them the ability to find younger patients with a NIHSS score at or above 10 without 
any medical comorbidity. Patients with more severe symptoms could be transported to 
locations that have an on call radiologist or the option of performing a CT angiography. The 
aim would be finding patients with a proximal arterial occlusion, ASPECTS score above 7 or 
a hyperdense MCA sign in time for relevant treatment. Needless to say, the goal should be 
limited time from onset of symptoms to initiation of treatment. This holds true but should on 
the other hand not exclude patients from being evaluated from further diagnostics with CT- or 
MR-perfusion scans seeing there are studies supporting recanalization several hours after the 
8 hour window that is now postulated. Accordingly, identifying patients with adequate 
collateral circulation is of crucial importance selecting patients for late starting therapy.  
        A lot of expectation is put into the use of stent retrievers that have proven superior to the 
earlier generation thrombectomy devices. However to prove their superiority against the 
present medical guidelines well organized randomized control studies with clear cut inclusion 
criteria are essential. Stroke treatment is still in its younger years and the full potential in 
terms of imaging and revascularization devices is yet to be seen. 
 
 
Conclusion 
After having reviewed a substantial amount of recent articles in the field, the following 
conclusion and recommendations can be drawn. Endovascular treatment in patients with acute 
ischemic stroke is shown to be a safe and efficient procedure and its aim should be to achieve 
a high recanalization rate keeping the time from onset of stroke symptoms to initiation of 
treatment to a minimum. Endovascular treatment can be used even up to 8 hours after start of 
symptoms but the time window might be even greater. Although there is still a discrepancy 
between successful recanalization and clinical outcome there are in fact predictors of positive 
and negative outcome suggesting whom to treat with the endovascular option. As of today 
goals should be focused on early identification of patients who might be eligible using 
adequate imaging techniques. To draw further conclusions whether or not endovascular 
therapy is superior to IVT large randomized controlled trials with clear inclusion criteria are 
needed. 
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